AbbVie Inc (ABBV)vsDefinitive Healthcare Corp (DH)
ABBV
AbbVie Inc
$246.04
+0.89%
HEALTHCARE · Cap: $430.82B
DH
Definitive Healthcare Corp
$0.71
+4.13%
HEALTHCARE · Cap: $72.31M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 26924% more annual revenue ($64.39B vs $238.26M). ABBV leads profitability with a 9.8% profit margin vs -71.5%. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
DH
Hold37
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-63.1%
Fair Value
$150.90
Current Price
$246.04
$95.14 premium
Margin of Safety
+77.8%
Fair Value
$7.63
Current Price
$0.71
$6.92 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 39.6%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
Elevated debt levels
ROE of -116.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.41 suggests the stock is reasonably priced for its growth.
Bull Case : DH
The strongest argument for DH centers on Price/Book.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 68.9x leaves little room for execution misses.
Bear Case : DH
The primary concerns for DH are EPS Growth, Market Cap, Debt/Equity.
Key Dynamics to Monitor
ABBV profiles as a value stock while DH is a turnaround play — different risk/reward profiles.
DH carries more volatility with a beta of 1.34 — expect wider price swings.
ABBV is growing revenue faster at 10.2% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (73/100 vs 37/100) and 10.2% revenue growth. DH offers better value entry with a 77.8% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Definitive Healthcare Corp
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Definitive Healthcare Corp (DH) is a leading provider of comprehensive data and analytics solutions designed specifically for the healthcare industry, catering to a diverse clientele that includes pharmaceutical companies, payers, and healthcare providers. By harnessing extensive datasets and cutting-edge real-time analytics, Definitive Healthcare enhances operational efficiencies and delivers critical strategic insights, ultimately improving patient outcomes. With a strong commitment to innovation, the company is well-positioned to capitalize on the growing demand for sophisticated healthcare analytics, thereby establishing itself as a pivotal player in the transformation of healthcare delivery.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?